Amplyx Pharmaceuticals, a San Diego, CA-based biotech company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, closed a $53m Series C extension, which brings the Series C round to over $90m.
The round was led by Sofinnova Investments, with participation from existing investors including New Enterprise Associates, Lundbeckfonden Ventures, Arix Bioscience, Pappas Capital, RiverVest Venture Partners, 3×5 Partners and BioMed Ventures. New equity investment from Pfizer Inc. (NYSE: PFE) and Adage Capital Management completed the financing round.
Led by Ciara Kennedy, Ph.D., president and chief executive officer, Amplyx Pharmaceuticals is developing innovative therapies for patients with compromised immune systems, including cancer and transplant patients, and the critically ill. The company’s two lead products are fosmanogepix (APX001), for the treatment of life-threatening fungal infections caused by pathogens such as Candida, Aspergillus and rare molds, and MAU868, a monoclonal antibody that potently neutralizes the BK virus, which can cause morbidity and mortality in transplant patients.
The company will use the proceeds of the financing to advance the clinical development of its product candidates, fosmanogepix and MAU868.